In this randomized , open-label trial , @ patients with advanced HCC throughout China were treated with @ % UBC three times per day plus best supportive care ( BSC ; n = @ ) or BSC alone excluding all creams ( n = @ ) , starting on day @ of sorafenib treatment , for up to @ weeks .